

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	3351663
<b>Application Number:</b>	10078949
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	8454
<b>Title of Invention:</b>	OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA
<b>First Named Inventor/Applicant Name:</b>	Stanley T. Crooke
<b>Customer Number:</b>	32650
<b>Filer:</b>	Jane E. Inglese/Heather Kite
<b>Filer Authorized By:</b>	Jane E. Inglese
<b>Attorney Docket Number:</b>	ISIS-5027
<b>Receipt Date:</b>	23-MAY-2008
<b>Filing Date:</b>	20-FEB-2002
<b>Time Stamp:</b>	15:04:42
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes) /Message Digest	Multi Part /.zip	Pages (if appl.)
1	Information Disclosure Statement Letter	ISIS-5027_SIDS_5-23-08.PDF	205859 915be46156f0abb96ac47226a09a4d0 97851353	no	26

### Warnings:

### Information:

2	Information Disclosure Statement (IDS) Filed	ISIS-5027_1449.PDF	155633 4fdce33699ccca222aab6ef9f13995d17cb0aeecc	no	3
<b>Warnings:</b>					
<b>Information:</b>					
	This is not an USPTO supplied IDS fillable form				
3	Foreign Reference	EP266168.pdf	541179 1514f093a077591dbd7c3de4b0547d6c7ca0770b	no	12
<b>Warnings:</b>					
<b>Information:</b>					
4	Foreign Reference	WO1994002498A1.pdf	1398746 f95d278687878e2c8130fb31c655d08025d87517	no	37
<b>Warnings:</b>					
<b>Information:</b>					
5	Foreign Reference	WO1996007392.pdf	2224316 53d1181df4a939b253fc48ab2ca65dbc13b87127	no	70
<b>Warnings:</b>					
<b>Information:</b>					
6	Foreign Reference	WO2002044321.pdf	4300156 408e33e5cc1b2479b1f4520902a7b9832ef55155	no	97
<b>Warnings:</b>					
<b>Information:</b>					
7	NPL Documents	Alahari_JPharmExpTher_1998_419-428.pdf	414972 51a2c86ec6b2c7cee216f524b96c7da547193843	no	10
<b>Warnings:</b>					
<b>Information:</b>					
8	NPL Documents	Beigelman_JBiolChem_1995_25702-25708.PDF	684865 cadd872ed0dd4c8024166cbf42ee0b2e54eb5bb	no	7
<b>Warnings:</b>					
<b>Information:</b>					
9	NPL Documents	Berger_NuclAcidsRes_1998_2473-2480.PDF	1176603 ddb113fa442f4118986000f3609ed19002c195d	no	8
<b>Warnings:</b>					
<b>Information:</b>					
10	NPL Documents	Bevilacqua_BioChem_1996_9983-9994.pdf	396526 bfeb693f15c485196dc5f59cacca8b52031561c	no	12

<b>Warnings:</b>					
<b>Information:</b>					
11	NPL Documents	Boutla_CurrBiol_2001_1776-1780.pdf	207849 94094fb64d545ce110a4ce684a9ff338e91664f0	no	5
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	Cook_AntiCancerDrugDes_585-607.pdf	3339117 46b4040b48fa5d9e817ca0f3d856d2c84dc8ef3b	no	23
<b>Warnings:</b>					
<b>Information:</b>					
13	NPL Documents	Damha_JAmChem_12976-12977.pdf	374132 7bf6d6429aa581f0148c9c046c5cf1d25b71b02f	no	2
<b>Warnings:</b>					
<b>Information:</b>					
14	NPL Documents	Elbashir_EMBOJ_2001_6877-6888.pdf	2125165 58c6d19f11fdc274e0f61a02b0a753adb0a076205	no	12
<b>Warnings:</b>					
<b>Information:</b>					
15	NPL Documents	hammond_Nature_2001_110-119.pdf	1068268 c94a9cecab3739e2b4bc65c4399ae1570e3dfc50	no	10
<b>Warnings:</b>					
<b>Information:</b>					
16	NPL Documents	Kimura-Harada_FEBSLett_335-338.pdf	260191 e7237ac45bcf27b165c11287da437db66553bf0	no	4
<b>Warnings:</b>					
<b>Information:</b>					
17	NPL Documents	Koizumi_NuclAcidsRes_1989_7059-7071.PDF	432548 97b3383e92c3b2b89143d21a145ed8d5e96aa23b	no	13
<b>Warnings:</b>					
<b>Information:</b>					
18	NPL Documents	Kuimelis_NuclAcidsRes_1994_1429-1436.PDF	615073 83a792663f1192189899f3b0809bd50fc37cb	no	8
<b>Warnings:</b>					
<b>Information:</b>					
19	NPL Documents	Lesnik_Biochem_1995_10807-10815.pdf	870577 27e3eee4a5ae16b4feab5392c4a97e1bcd586a55	no	9

<b>Warnings:</b>					
<b>Information:</b>					
20	NPL Documents	Parrish_Molecular_Cell_2000_1077_1087.PDF	852241 2fba500e934d0f3778ea3f7c6516720ead26b7ff	no	11
<b>Warnings:</b>					
<b>Information:</b>					
21	NPL Documents	Porta_Biotechnol_161-164.PDF	416967 9c115bdb0cc88a0ff9c18a7c986ef201ca6529371	no	4
<b>Warnings:</b>					
<b>Information:</b>					
22	NPL Documents	Shuman_JBiolChem_1993_18943-18950.PDF	1057587 064554f5c2d907c87fd51cfa22acbcbe725919	no	8
<b>Warnings:</b>					
<b>Information:</b>					
23	NPL Documents	Tosquellas_2069-2074.pdf	748954 982e2f21f70db26b1ed6d13345a8d4ec0e343941	no	6
<b>Warnings:</b>					
<b>Information:</b>					
24	NPL Documents	Tracewell_ToxicolApplPharmacol_179-184.pdf	533926 40317e01fceceebd40c4dac78f24480eb7d49b7	no	6
<b>Warnings:</b>					
<b>Information:</b>					
25	NPL Documents	Tuschl_MolIntervent_158-167.pdf	585527 ab6bb91ca28e9d6adc00c6829546edc0b453987	no	10
<b>Warnings:</b>					
<b>Information:</b>					
26	NPL Documents	Veronese_NuclAcidsRes_3625-3635.pdf	1854952 3497ac5194b5e40052b54a2689ac1398b2a82ac9	no	20
<b>Warnings:</b>					
<b>Information:</b>					
27	NPL Documents	Wilds_NuclAcidsRes_3625-3635.pdf	993593 0119a4ec26b0f4dc9e6993690ee43a0a73a2648	no	11
<b>Warnings:</b>					
<b>Information:</b>					
28	NPL Documents	Wu_JBiolChem_2532-2542.pdf	1469078 51fa5f6647b90d1ec0c18c52a08e714da50a91d7	no	11

<b>Warnings:</b>					
<b>Information:</b>					
29	NPL Documents	Yu_RNA_324-331.pdf	5741301 fd9f93e779d231e7eb6f15effd7920d6ef b42041	no	8
<b>Warnings:</b>					
<b>Information:</b>					
30	NPL Documents	Yu_BioorgMedChem_1685-1 692.pdf	686717 04f97d47a0a6bf161a313394ad52302a 21efa5bc	no	7
<b>Warnings:</b>					
<b>Information:</b>					
31	NPL Documents	Table_rej.PDF	137196 836ce7c5784a57536f8426d8a9f822e3 e9628917	no	24
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>				35869814	
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><b>New Applications Under 35 U.S.C. 111</b>  If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><b>National Stage of an International Application under 35 U.S.C. 371</b>  If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><b>New International Application Filed with the USPTO as a Receiving Office</b>  If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					